| Gerald P Spindel, MD | |
|
6 Tsienneto Rd, Suite 101, Derry, NH 03038 | |
| (603) 434-4193 | |
| Not Available |
| Full Name | Gerald P Spindel |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 43 Years |
| Location | 6 Tsienneto Rd, Derry, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750463162 | NPI | - | NPPES |
| 00000426 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 151290 (Massachusetts) | Secondary |
| 207W00000X | Ophthalmology | 7104 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Spindel Eye Associates Pc | 4880676659 | 10 |
News Archive
Scientists using high-powered microscopes have made a stunning observation of the architecture within a cell - and identified for the first time how the architecture changes during the formation of gametes, also known as sex cells, in order to successfully complete the process.
Scientists at the Buck Institute for Age Research have shown that combining two environmental toxic substances accelerated age-related degeneration in neurons associated with Parkinson's disease (PD) in mice.
Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Men and women who walk or ride a bike to work appear more fit, and men are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure and insulin levels, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 8 days ago
| Entity Name | Spindel Eye Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952471807 PECOS PAC ID: 4880676659 Enrollment ID: O20040604000386 |
News Archive
Scientists using high-powered microscopes have made a stunning observation of the architecture within a cell - and identified for the first time how the architecture changes during the formation of gametes, also known as sex cells, in order to successfully complete the process.
Scientists at the Buck Institute for Age Research have shown that combining two environmental toxic substances accelerated age-related degeneration in neurons associated with Parkinson's disease (PD) in mice.
Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Men and women who walk or ride a bike to work appear more fit, and men are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure and insulin levels, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gerald P Spindel, MD 6 Tsienneto Rd, Suite 101, Derry, NH 03038 Ph: (603) 434-4193 | Gerald P Spindel, MD 6 Tsienneto Rd, Suite 101, Derry, NH 03038 Ph: (603) 434-4193 |
News Archive
Scientists using high-powered microscopes have made a stunning observation of the architecture within a cell - and identified for the first time how the architecture changes during the formation of gametes, also known as sex cells, in order to successfully complete the process.
Scientists at the Buck Institute for Age Research have shown that combining two environmental toxic substances accelerated age-related degeneration in neurons associated with Parkinson's disease (PD) in mice.
Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' proprietary technology to empower antibodies by linking them to potent cell-killing drugs.
Men and women who walk or ride a bike to work appear more fit, and men are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure and insulin levels, according to a report in the July 13 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 8 days ago
Dr. David Fridrich Vazan, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd, Suite 101, Derry, NH 03038 Phone: 603-434-4193 Fax: 603-437-6804 | |
Mohamed A Guenena, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 6 Tsienneto Rd Ste 101, Derry, NH 03038 Phone: 603-434-4193 Fax: 603-437-6804 |